98 related articles for article (PubMed ID: 24909516)
1. Tubulin inhibitors: pharmacophore modeling, virtual screening and molecular docking.
Niu MM; Qin JY; Tian CP; Yan XF; Dong FG; Cheng ZQ; Fida G; Yang M; Chen HY; Gu YQ
Acta Pharmacol Sin; 2014 Jul; 35(7):967-79. PubMed ID: 24909516
[TBL] [Abstract][Full Text] [Related]
2. 3D-QSAR-Based Pharmacophore Modeling, Virtual Screening, and Molecular Docking Studies for Identification of Tubulin Inhibitors with Potential Anticancer Activity.
Mirzaei S; Ghodsi R; Hadizadeh F; Sahebkar A
Biomed Res Int; 2021; 2021():6480804. PubMed ID: 34485522
[TBL] [Abstract][Full Text] [Related]
3. Structure-Based Pharmacophore Design and Virtual Screening for Novel Tubulin Inhibitors with Potential Anticancer Activity.
Zhou Y; Di B; Niu MM
Molecules; 2019 Sep; 24(17):. PubMed ID: 31480625
[TBL] [Abstract][Full Text] [Related]
4.
Hadizadeh F; Ghodsi R; Mirzaei S; Sahebkar A
Comput Math Methods Med; 2022; 2022():4004068. PubMed ID: 35075369
[TBL] [Abstract][Full Text] [Related]
5. Identification of Novel β-Tubulin Inhibitors Using a Combined
Horgan MJ; Zell L; Siewert B; Stuppner H; Schuster D; Temml V
J Chem Inf Model; 2023 Oct; 63(20):6396-6411. PubMed ID: 37774242
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a Dual Tubulin and Neuropilin-1 (NRP1) Inhibitor with Potent In Vivo Anti-Tumor Activity via Pharmacophore-based Docking Screening, Structure Optimization, and Biological Evaluation.
Zheng L; Zou Y; Xie T; Wu X; Tan Y; Mei S; Geng Y; Chen S; Xu S; Niu MM
J Med Chem; 2023 Dec; 66(23):16187-16200. PubMed ID: 38093696
[TBL] [Abstract][Full Text] [Related]
7. Fragment based group QSAR and molecular dynamics mechanistic studies on arylthioindole derivatives targeting the α-β interfacial site of human tubulin.
Tyagi C; Gupta A; Goyal S; Dhanjal J; Grover A
BMC Genomics; 2014; 15 Suppl 9(Suppl 9):S3. PubMed ID: 25521775
[TBL] [Abstract][Full Text] [Related]
8. Exploration of Novel PDEδ Inhibitor Based on Pharmacophore and Molecular Docking against KRAS Mutant in Colorectal Cancer.
Mouhcine M; Kadil Y; Rahmoune I; Filali H
Curr Drug Discov Technol; 2023; 20(4):e160423215830. PubMed ID: 37066770
[TBL] [Abstract][Full Text] [Related]
9. Lead generation of UPPS inhibitors targeting MRSA: Using 3D-QSAR pharmacophore modeling, virtual screening, molecular docking, and molecular dynamic simulations.
Qandeel BM; Mowafy S; Abouzid K; Farag NA
BMC Chem; 2024 Jan; 18(1):14. PubMed ID: 38245752
[TBL] [Abstract][Full Text] [Related]
10. 3D QSAR pharmacophore modeling, in silico screening, and density functional theory (DFT) approaches for identification of human chymase inhibitors.
Arooj M; Thangapandian S; John S; Hwang S; Park JK; Lee KW
Int J Mol Sci; 2011; 12(12):9236-64. PubMed ID: 22272131
[TBL] [Abstract][Full Text] [Related]
11. 3D pharmacophore mapping using 4D QSAR analysis for the cytotoxicity of lamellarins against human hormone-dependent T47D breast cancer cells.
Thipnate P; Liu J; Hannongbua S; Hopfinger AJ
J Chem Inf Model; 2009 Oct; 49(10):2312-22. PubMed ID: 19799437
[TBL] [Abstract][Full Text] [Related]
12. The discovery of a novel IκB kinase β inhibitor based on pharmacophore modeling, virtual screening and biological evaluation.
Li L; Gong S
Future Med Chem; 2024 Mar; 16(6):531-544. PubMed ID: 38385164
[TBL] [Abstract][Full Text] [Related]
13. Identification of small molecular inhibitors of SIRT3 by computational and biochemical approaches a potential target of breast cancer.
Ullah A; Rehman NU; Islam WU; Khan F; Waqas M; Halim SA; Jan A; Muhsinah AB; Khan A; Al-Harrasi A
Sci Rep; 2024 May; 14(1):12475. PubMed ID: 38816444
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore modeling, docking and the integrated use of a ligand- and structure-based virtual screening approach for novel DNA gyrase inhibitors: synthetic and biological evaluation studies.
Mathpal D; Masand M; Thomas A; Ahmad I; Saeed M; Zaman GS; Kamal M; Jawaid T; Sharma PK; Gupta MM; Kumar S; Srivastava SP; Balaramnavar VM
RSC Adv; 2021 Oct; 11(55):34462-34478. PubMed ID: 35494744
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel JAK1 inhibitors through combining machine learning, structure-based pharmacophore modeling and bio-evaluation.
Wang Z; Sun L; Xu Y; Liang P; Xu K; Huang J
J Transl Med; 2023 Aug; 21(1):579. PubMed ID: 37641144
[TBL] [Abstract][Full Text] [Related]
16. Identification of DNA Methyltransferase-1 Inhibitor for Breast Cancer Therapy through Computational Fragment-Based Drug Design.
Alkaff AH; Saragih M; Imana SN; Nasution MAF; Tambunan USF
Molecules; 2021 Jan; 26(2):. PubMed ID: 33450856
[TBL] [Abstract][Full Text] [Related]
17. Tubulin Inhibitors: A Chemoinformatic Analysis Using Cell-Based Data.
López-López E; Cerda-García-Rojas CM; Medina-Franco JL
Molecules; 2021 Apr; 26(9):. PubMed ID: 33923169
[TBL] [Abstract][Full Text] [Related]
18. Molecular docking and structure-based drug design strategies.
Ferreira LG; Dos Santos RN; Oliva G; Andricopulo AD
Molecules; 2015 Jul; 20(7):13384-421. PubMed ID: 26205061
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel Akt1 inhibitors by an ensemble-based virtual screening method, molecular dynamics simulation, and in vitro biological activity testing.
Zhang W; Hu ML; Shi XY; Chen XL; Su X; Qi HZ; Yuan L; Zhang H
Mol Divers; 2024 Jan; ():. PubMed ID: 38240951
[TBL] [Abstract][Full Text] [Related]
20. First chemical feature-based pharmacophore modeling of potent retinoidal retinoic acid metabolism blocking agents (RAMBAs): identification of novel RAMBA scaffolds.
Purushottamachar P; Patel JB; Gediya LK; Clement OO; Njar VC
Eur J Med Chem; 2012 Jan; 47(1):412-23. PubMed ID: 22130607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
